Aprea Therapeutics, Inc.

APRE

US03836J2015

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:15:14 2024-04-24 pm EDT			5-day change	1st Jan Change
5.17 ^USD	-3.72%		-9.77%	+10.00%

Apr. 10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI
Mar. 27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT

Aprea Therapeutics, Inc.(NasdaqGS:APRE) added to Russell 3000E Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	Apr. 10	CI
Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	Mar. 27	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26	MT
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051	Mar. 14	CI
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	Mar. 11	CI
Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insiders	Mar. 10	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Aprea Therapeutics Files $150 Million Mixed Shelf; Shares Fall	Jan. 26	MT
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	Jan. 04	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Aprea Therapeutics, Inc. - Special Call	23-10-31
Aprea Therapeutics, Inc. Announces Preclinical Data Supporting Highly Differentiated Wee1 Inhibitor, Atrn-1051, Reliable to Other Wee1 Inhibitors	23-09-11	CI
Aprea Therapeutics, Inc. Announces Board Changes	23-08-24	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Certain Series A Preferred Stock of Aprea Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2023.	23-05-23	CI
Certain Options of Aprea Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2023.	23-05-23	CI
Certain Restricted Stock Units of Aprea Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2023.	23-05-23	CI
Certain Common Stock of Aprea Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2023.	23-05-23	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Aprea Therapeutics, Inc. Appoints Gabriela Gruia to Board of Directors	23-05-08	CI
Wedbush Raises Aprea Therapeutics' PT to $9 From $3, Says Keeps Outperform Rating; Continues to View Shares as 'Intriguingly Valued'	23-04-10	MT
North American Morning Briefing : Stock Futures -2-	23-03-27	DJ

Chart Aprea Therapeutics, Inc.

Duration

Period

More charts

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aprea Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.37 USD

Average target price

15.67 USD

Spread / Average Target

+191.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APREA THERAPEUTICS, INC.	+10.00%	29.16M
IQVIA HOLDINGS INC.	+3.65%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.18%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.88%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.77%	18.47B
MEDPACE HOLDINGS, INC.	+29.49%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.74%	12.33B
UNITED THERAPEUTICS CORPORATION	+8.17%	11.03B

Other Biotechnology & Medical Research